Cullinan Therapeutics公司公布了其候选药物CLN-978(一种CD19 T细胞衔接器)在EULAR大会上展示的数据。数据显示,该药物在系统性红斑狼疮和类风湿关节炎患者中均表现出诱导免疫重置的潜力,其中包含了疾病缓解的案例。
Cullinan Therapeutics公司公布了其候选药物CLN-978(一种CD19 T细胞衔接器)在EULAR大会上展示的数据。数据显示,该药物在系统性红斑狼疮和类风湿关节炎患者中均表现出诱导免疫重置的潜力,其中包含了疾病缓解的案例。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.